Fig. 5From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART studyResponses to convenience questionnaire (n = 58). Mean scores and standard error bars are shownBack to article page